0001415889-24-016351.txt : 20240611
0001415889-24-016351.hdr.sgml : 20240611
20240611161347
ACCESSION NUMBER: 0001415889-24-016351
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240609
FILED AS OF DATE: 20240611
DATE AS OF CHANGE: 20240611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stueland Katherine
CENTRAL INDEX KEY: 0001689575
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39482
FILM NUMBER: 241035910
MAIL ADDRESS:
STREET 1: 458 BRANNAN STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GeneDx Holdings Corp.
CENTRAL INDEX KEY: 0001818331
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 851966622
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 617 780 8742
MAIL ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Sema4 Holdings Corp.
DATE OF NAME CHANGE: 20210721
FORMER COMPANY:
FORMER CONFORMED NAME: CM Life Sciences, Inc.
DATE OF NAME CHANGE: 20200715
4
1
form4-06112024_080643.xml
X0508
4
2024-06-09
0001818331
GeneDx Holdings Corp.
WGS
0001689575
Stueland Katherine
C/O GENEDX HOLDINGS CORP.
333 LUDLOW ST., NORTH TOWER
STAMFORD
CT
06902
true
true
false
false
Chief Executive Officer
0
Class A Common Stock
2024-06-09
4
M
0
6546
0
A
82415
D
Class A Common Stock
2024-06-10
4
S
0
2652
24.92
D
79763
D
Restricted Stock Unit
2024-06-09
4
M
0
6546
0
D
Class A Common Stock
6546
65465
D
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to
cover" transaction
6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
/s/ Devin Schaffer, Attorney-in-Fact
2024-06-11